Rockwell Medical

364 articles with Rockwell Medical

• Rockwell Medical Named 'Great Place to Work'

  2/28/2023

  Rockwell Medical, Inc. announced that it has been certified as a Great Place to Work® in 2023, the Company's inaugural year participating in the accreditation.

• Rockwell Medical to Release Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30, 2023

  2/16/2023

  Rockwell Medical, Inc. announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2022 on Thursday, March 30, 2023.

• Rockwell Medical and Concerto Renal Services Establish New Three-Year, Multi-Million Dollar Product Purchase Agreement

  2/13/2023

  Rockwell Medical, Inc. announced that the Company signed a three-year product purchase agreement with Concerto Renal Services, the largest provider of dialysis in skilled nursing facilities in the United States.

• Rockwell Medical Signs Three-Year, Multi-Million Dollar Supply Agreement with Largest Non-Profit Dialysis Provider in the United States

  2/2/2023

  Rockwell Medical, Inc. announced that the Company signed a three-year, multi-million dollar per annum product purchase agreement with the largest non-profit dialysis provider in the United States.

• Rockwell Medical Begins Selling its Hemodialysis Concentrates Products to New Clinics in Minnesota with its Largest Customer

  12/13/2022

  Rockwell Medical, Inc., a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that the Company is adding new business within the Minnesota region.

• Rockwell Medical Provides Business Strategy Update and Announces Third Quarter 2022 Financial and Operational Results

  11/14/2022

  Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today provided an update on its overall business strategy and announced its financial and operational results for the third quarter ended September 30, 2022.

• Rockwell Medical to Release Third Quarter 2022 Financial Results on Monday, November 14

  10/17/2022

  Rockwell Medical, Inc. announced that it will release its financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022.

• Rockwell Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

  9/14/2022

  Rockwell Medical, Inc. today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of stock options to purchase an aggregate of 66,000 shares of the Company’s common stock.

• Rockwell Medical Names Heather Hunter SVP, Chief Corporate Affairs Officer

  9/7/2022

  Rockwell Medical, Inc. announced that Heather Hunter has joined the Company as SVP, Chief Corporate Affairs Officer.

• Rockwell Medical Announces Second Quarter 2022 Results

  8/15/2022

  Rockwell Medical, Inc., a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced its financial and operational results for the second quarter ended June 30, 2022.

• Rockwell Medical to Release Second Quarter 2022 Financial Results on Monday, August 15

  8/3/2022

  Rockwell Medical, Inc., a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that it will release its financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022.

• Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer

  6/22/2022

  Rockwell Medical , Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck , Ph.D., as President and Chief Executive Officer, effective July 1, 2022.

• Rockwell Medical Provides Corporate and Clinical Update

  6/22/2022

  Rockwell Medical, Inc. (Nasdaq: RMTI), today provided an update on its recent capital raise and a clinical update on safety enhancements to its planned Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC) in home infusion patients.

• Rockwell Medical Regains Compliance with Nasdaq Listing Requirements - June 01, 2022

  6/1/2022

  Rockwell Medical, Inc. announced that it received notice from The NASDAQ Stock Market LLC on May 31, 2022 informing Rockwell Medical that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on The NASDAQ Capital Market.

• Rockwell Medical, Inc. to Present at H.C. Wainwright Annual Global Life Sciences Conference

  5/23/2022

  Rockwell Medical, Inc. announced that Russell Ellison, M.D., M.Sc., President and Chief Executive Officer is scheduled to present at H.C. Wainwright's Annual Global Life Sciences Conference in Miami, Florida on Tuesday, May 24th at 3:30 PM ET.

• Rockwell Medical Provides First Quarter 2022 Financial and Operational Update

  5/16/2022

  Rockwell Medical, Inc. reported financial results and a business update for the three months ended March 31, 2022.

• Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

  5/12/2022

  Rockwell Medical, Inc. (Nasdaq: RMTI), today announced that it provided the U.S. Food and Drug Administration (FDA) with the supplemental data, requested by the agency in December 2021, for the Company's pending Investigational New Drug (IND) application in support of a proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC).

• Rockwell Medical Announces 1-for-11 Reverse Stock Split

  5/12/2022

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, announced that its Board of Directors has approved a 1-for-11 reverse split of the Company's issued and outstanding common stock.

• Rockwell Medical, Inc. to Report First Quarter 2022 Financial and Operating Results on May 16, 2022

  5/11/2022

  Rockwell Medical , Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, May 16 at 4:15 PM ET to discuss its financial results for the three months ended March 31, 2022, and recent operational highlights.

• 

  Clinical Catch-Up: Genentech Announces Positive Data, Pfizer Develops New Vaccine

  5/2/2022

  A roundup of last week's top clinical trial updates and news.